Cadila Healthcare’s wholly owned subsidiary Zydus Pharmaceuticals; through its US subsidiary Zynesher Pharmaceuticals USA has entered into an agreement to acquire the asset of the US based Pharmaceutical company Nesher Pharmaceuticals. Nesher operates as the generic subsidiary of KV Pharmaceuticals based at St. Louis. Missouri. USA.
Nesher has substantial expertise in niche therapies which have development or production barriers, such as controlled release medications or FDA controlled substances. With this Zydus will be able to manufacture and distribute generic controlled substances in the American market, which otherwise cannot be imported. The Purchase agreement contains Nisher’s existing and pipeline assets and assumption of certain liabilities. The agreement also covers supply and technical services by which certain products of the KV Pharmaceutical will be manufactured by Zynesher pharmaceuticals USA.
Cadila Pharmaceuticals focuses on various areas, such as formulations (human & veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.
